Carney syndrome is a dubious disease in the field of blood tumours, with complex clinical outcomes and often involving multi-system congestion. Early identification and standardised clinical care are essential for improving prognosis. The diagnosis of Carney syndrome requires a comprehensive assessment platform including clinical outcomes, imaging, laboratory testing and pathological activation.
A team of authoritative experts at home and abroad can assist in providing accurate diagnosis and treatment. Individual treatment plans for treatment and management of Carney syndrome are required, usually including drug therapy, rehabilitation intervention, and regular follow-up to multiple-dimensional management. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many previously difficult to treat blood tumour diseases have been significantly improved.
Treatment requires close monitoring of efficacy and adverse reactions and timely adjustment according to changes in the condition. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of Carney syndrome. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.